Publication date: Jul 30, 2019 This post was originally published on this site Treatment with EIP Pharma’s investigational therapy neflamapimod (VX-745) can restore nerve cells’ communications and prevent their progressive ... Read more

Publication date: Jul 23, 2019 This post was originally published on this site EIP Pharma is launching a proof-of-concept Phase 2 clinical trial to assess the ability of therapeutic candidate ... Read more

Publication date: Jul 18, 2019 ^A “The findings add to the growing body of evidence that inhibition of p38 alpha kinase has the potential to reverse synaptic dysfunction and treat ... Read more

Publication date: Jul 10, 2019 CAMBRIDGE, Massachusetts, July 9, 2019 /PRNewswire/ — EIP Pharma, Inc. , a CNS-focused therapeutics company, today announced the initiation of a new Phase 2 proof-of-concept ... Read more

Publication date: Jun 10, 2019 This is a double-blind, placebo-controlled 2-period 10-week treatment within-subject crossover study of neflamapimod in early-stage Huntington disease (HD). The primary objective is to determine whether ... Read more

Publication date: Aug 20, 2019 Siew Jian Jing (蕭建靖), leading scientist for the research published in the journal Nature Communications Aug. 2, said the team has found the novel role ... Read more